Interestingly, CMTM2, FOS, PIK3CB, SOS2, TLR4, IL18R1, CMTM6, and FPR1 were coregulated to regulate the SLE immune response, supporting the use of the biomarkers mentioned above in combination immunotherapy in future studies. This evidence concerns the gene CMTM2 and systemic lupus erythematosus.